Thrombolytic therapy : 2001MARDER, V. J.Blood reviews. 2001, Vol 15, Num 3, pp 143-157, issn 0268-960XArticle

What does the dimertest test ?MARDER, V. J.Circulation (New York, N.Y.). 1990, Vol 82, Num 4, pp 1514-1515, issn 0009-7322Article

Thrombolytic therapy : reocclusion rates with adjunctive aspirin and its relation to heparin therapySHERRY, S; MARDER, V. J.Journal of the American College of Cardiology. 1992, Vol 19, Num 3, pp 678-680, issn 0735-1097Article

Creation of the recombinant tissue plasminogen activator (rt-PA) image and its influence on practice habitsSHERRY, S; MARDER, V. J.Journal of the American College of Cardiology. 1991, Vol 18, Num 6, pp 1579-1582, issn 0735-1097Article

Thrombolytic therapy: current status. (first of two parts)MARDER, V. J; SHERRY, S.The New England journal of medicine. 1988, Vol 318, Num 23, pp 1512-1520, issn 0028-4793Article

Streptokinase and recombinant tissue plasminogen activator (rt-PA) are equally effective in treating acute myocardial infarctionSHERRY, S; MARDER, V. J.Annals of internal medicine. 1991, Vol 114, Num 5, pp 417-423, issn 0003-4819, 7 p.Article

Thrombolytic therapy: current status. IIMARDER, V. J; SHERRY, S.The New England journal of medicine. 1988, Vol 318, Num 24, pp 1585-1595, issn 0028-4793Article

Mistaken guidelines for thrombolytic therapy of acute myocardial infarction in the elderlySHERRY, S; MARDER, V. J.Journal of the American College of Cardiology. 1991, Vol 17, Num 5, pp 1237-1238, issn 0735-1097, 2 p.Article

Thrombosis, fibrinolysis, and thrombolytic therapy : a perspectiveSHERRY, S; MARDER, V. J.Progress in cardiovascular diseases. 1991, Vol 34, Num 2, pp 89-100, issn 0033-0620Article

How have trials of thrombolytics influenced clinical management of patients with acute myocardial infarctionMARDER, V. J.Thrombosis and haemostasis. 1997, Vol 78, Num 1, pp 548-552, issn 0340-6245Conference Paper

Plasma crosslinked fibrin polymers : quantiation based on tissue plasminogen activator conversion to D-dimer and measurement in normals and patients with acute thrombotic disordersABRAHAM KORNBERG; FRANCIS, C. W; MARDER, V. J et al.Blood. 1992, Vol 80, Num 3, pp 709-717, issn 0006-4971Article

Degradation of cross-linked fibrin by human leukocyte proteasesFRANCIS, C. W; MARDER, V. J.The Journal of laboratory and clinical medicine. 1986, Vol 107, Num 4, pp 342-352, issn 0022-2143Article

Biosynthesis of von Willebrand protein by human endothelial cells: processing steps and their intracellular localizationWAGNER, D. D; MARDER, V. J.The Journal of cell biology. 1984, Vol 99, Num 6, pp 2123-2130, issn 0021-9525Article

Thrombolytic therapy for acute transmural myocardial infarction: intracoronary versus intravenousMARDER, V. J; FRANCIS, C. W.The American journal of medicine. 1984, Vol 77, Num 5, pp 921-928, issn 0002-9343Article

Cocaine and Buerger disease: Is there a pathogenetic association?MARDER, V. J; MELLINGHOFF, I. K.Archives of internal medicine (1960). 2000, Vol 160, Num 13, pp 2057-2060, issn 0003-9926Article

Thrombolytic therapy : overview of results in major vascular occlusionsMARDER, V. J.Thrombosis and haemostasis. 1995, Vol 74, Num 1, pp 101-105, issn 0340-6245Conference Paper

Fibrinolytic therapy for venous thrombosisFRANCIS, C. W; MARDER, V. J.Progress in cardiovascular diseases. 1991, Vol 34, Num 3, pp 193-204, issn 0033-0620Article

Low-molecular-weight heparins _ New frontiers in antithrombotic therapyKAKKAR, V. V; MARDER, V. J.Haemostasis. 1997, Vol 27, issn 0301-0147, 49 p., SUP1Conference Proceedings

Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit modelMONTONEY, M; GARDELL, S. J; MARDER, V. J et al.Circulation (New York, N.Y.). 1995, Vol 91, Num 5, pp 1540-1544, issn 0009-7322Article

Rapid formation of large molecular weight α-polymers in cross-linked fibrin induced by high factor XIII concentrations: role of platelet factor XIIIFRANCIS, C. W; MARDER, V. J.The Journal of clinical investigation. 1987, Vol 80, Num 5, pp 1459-1465, issn 0021-9738Article

Initial glycosylation and acidic pH in the Golgi apparatus are required for multimerization of von Willebrand factorWAGNER, D. D; MAYADAS, T; MARDER, V. J et al.The Journal of cell biology. 1986, Vol 102, Num 4, pp 1320-1324, issn 0021-9525Article

Streptokinase and anisoylated lys-plasminogen streptokinase activator complexMARDER, V. J; BACHMANN, F.Handbook of experimental pharmacology. 2001, Vol 146, pp 173-208, issn 0171-2004Article

DDAVP reduces bleeding during continued hirudin administration in the rabbitBOVE, C. M; CASEY, B; MARDER, V. J et al.Thrombosis and haemostasis. 1996, Vol 75, Num 3, pp 471-475, issn 0340-6245Article

The role of soluble cross-linked fibrin in D dimer immunoreactivity of plasmic digestsBRENNER, B; FRANCIS, C. W; MARDER, V. J et al.The Journal of laboratory and clinical medicine. 1989, Vol 113, Num 6, pp 682-688, issn 0022-2143Article

Increased resistance to plasmic degradation of fibrin with highly crosslinked α-polymer chains formed at high factor XIII concentrationsFRANCIS, C. W; MARDER, V. J.Blood. 1988, Vol 71, Num 5, pp 1361-1365, issn 0006-4971Article